

1 **The urothelial transcriptomic response to interferon gamma predicts T1 recurrence-free**  
2 **and basal/squamous muscle-invasive bladder cancer survival and better targeted**  
3 **strategies for immune checkpoint blocking.**

4 Simon C. Baker<sup>1,\*</sup>, Andrew S. Mason<sup>1</sup>, Raphael G. Slip<sup>1</sup>, Pontus Eriksson<sup>2</sup>, Gottfrid Sjö Dahl<sup>2</sup>,  
5 Ludwik K Trejdosiewicz<sup>1</sup> and Jennifer Southgate<sup>1</sup>.

6

7 Affiliation

8 <sup>1</sup>Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical  
9 Research Institute, University of York, Heslington, York YO10 5DD, UK.

10 <sup>2</sup>Lund University Cancer Centre, Lunds Universitet, Box 117, 221 00 Lund, Sweden.

11

12 Contact Information for Corresponding Author\* (Address as above)

13 Tel: +44 1904 328706

14 E-mail address: [simon.baker@york.ac.uk](mailto:simon.baker@york.ac.uk)

15

16 Keywords: urothelium, IFNg, non muscle invasive bladder cancer, APOBEC

## 17 **Abstract**

18 Intravesical Bacillus Calmette-Guérin vaccine (BCG) is an established immunotherapeutic in  
19 bladder cancer (BlCa), provoking inflammation leading to tumour-specific immunity. Immune  
20 checkpoint blockers such as anti-PD-L1 have potential for enhancing tumour-specific  
21 lymphocyte-mediated cytotoxicity in BCG-refractive or advanced disease. In both cases,  
22 Interferon-gamma (IFN $\gamma$ ) plays a central role. We investigated the transcriptomic response of  
23 normal human urothelium to IFN $\gamma$  to disentangle mechanisms of BCG and anti-PD-L1 therapy  
24 failure.

25 Exposure of differentiated human urothelium to IFN $\gamma$  resulted in upregulated MHC class I and  
26 class II and *de novo* expression of CXCL9-11 chemokine genes. Normal urothelium expressed  
27 only immuno-inhibitory B7 family members: PD-L1 expression was induced by IFN $\gamma$ , whereas  
28 VISTA was expressed constitutively.

29 A urothelial IFN $\gamma$  response gene set was derived and used for unsupervised clustering of  
30 tumours, which predicted longer recurrence-free survival in non-muscle invasive bladder  
31 cancer (NMIBC). In muscle invasive bladder cancer (MIBC), the IFN $\gamma$ -signature split the  
32 basal/squamous consensus subtype, with significantly worse overall survival when  
33 weak/absent.

34 Normal urothelium has few resident lymphocytes. Tumour cell killing requires recruitment  
35 and activation of IFN $\gamma$ -secreting pro-inflammatory/cytotoxic lymphocytes while surmounting  
36 both innate (VISTA) and upregulated (PD-L1) inhibitory mechanisms. This study offers  
37 supportive evidence for strategies to enhance immunotherapy *via* the IFN $\gamma$  and VISTA/PD-L1  
38 nexus.

39 **Patient Summary**

40 Immunotherapy brings promise of harnessing a patient's own immune system to seek and  
41 destroy malignant cells, but it has yet to deliver widespread clinical benefit. We exposed  
42 human urothelium to interferon gamma, a key messenger of the immune system and  
43 identified a novel signature of 33 genes that predicted cancers with better outcomes. Our  
44 study revealed alternative strategies for targeting checkpoint proteins to improve  
45 immunotherapy in the future.

46 **Manuscript**

47 BCG is widely used in NMIBC therapy as a potent inducer of inflammation, provoking  
48 infiltration by IFN $\gamma$ -secreting proinflammatory leukocytes which become exposed to tumour  
49 neoantigens, resulting in tumour-specific immunity [1]. In an orthotopic MB49 mouse BICa  
50 model, IFN $\gamma$  was critical for intrinsic tumour surveillance and an *Ifng*-knockout rendered BCG  
51 ineffective [2].

52 We report the results of exposing mitotically-quiescent (G0-arrested), *in vitro*-differentiated  
53 normal human urothelium from six independent donors to 200 U/mL IFN $\gamma$  to generate a  
54 tissue-specific urothelial response transcriptome. mRNA-sequencing identified 107 genes  
55 significantly ( $q < 0.05$ ) >2-fold increased by seven-day exposure to IFN $\gamma$  (Fig. 1A and  
56 Supplementary Table 1).

57 The IFN $\gamma$  receptor genes (*IFNGR1* and *IFNGR2*) were abundantly expressed by urothelium  
58 (Supplementary Fig. 1). In all six donors, irrespective of haplotype, IFN $\gamma$  induced gain of human  
59 leukocyte antigen (HLA) gene expression associated with both major histocompatibility  
60 complex (MHC) class I and class II (Supplementary Fig. 2). Gains in expression of  $\beta$ 2-  
61 microglobulin (*B2M*), MHC class II invariant chain (*CD74*) and trans-activator (*CIITA*), as well  
62 as the antigen peptide transporters *TAP1* and *TAP2*, suggest an induced role in modulating  
63 antigen-presentation to CD4 T cells (Supplementary Fig. 2). However, urothelial cells are  
64 unlikely to act as professional antigen presenting cells, because the co-stimulatory B7 family  
65 CD80 and CD86 genes were absent and were not inducible by IFN $\gamma$  (Fig. 1C).

66 Blocking antibodies against the PD-L1 (CD274) immune checkpoint have been trialled clinically  
67 to disinhibit tumour-specific cytotoxic lymphocytes. *CD274* (PD-L1) was strongly induced by  
68 IFN $\gamma$  (Fig. 1C). By contrast, the inhibitory B7 family member *VSIR* (VISTA) was expressed

69 constitutively by normal human urothelium but has to-date been overlooked in the bladder  
70 [3]. This indicates that normal urothelium, and likely its malignant counterpart, is a locally  
71 immunosuppressive environment, with induction of PD-L1 by IFN $\gamma$  acting as a negative  
72 feedback loop to prevent runaway inflammation.

73 IFN $\gamma$ -treatment induced a shift in expression of chemokines and cytokines implicated in  
74 immune recruitment, with loss (*CCL20*, *CXCL8*, *CXCL1*, *CXCL6*, *IL23A*, *IL1B*, *IL17C*, *CXCL5* and  
75 *CXCL2*) and gain (*CXCL11*, *CXCL10*, *CXCL9*, *IL18BP*, *IL32*) of different signalling factors (Fig. 1B).  
76 Of particular note, the *CXCL9/10/11*-*CXCR3* axis is a critical regulator of leukocyte migration,  
77 differentiation and activation [4], including recruitment of effector T cells. We have shown  
78 elsewhere that *CXCL10/11* are highly induced following exposure of normal urothelium to BK  
79 virus [5] and were the only genes to be further upregulated, rather than repressed, by  
80 treatment with exogenous IFN $\gamma$ . We therefore suggest that attenuated BK virus could be used  
81 to generate a pro-inflammatory, IFN $\gamma$ -rich local environment akin to that induced by BCG.

82 Cancer subtyping is usually performed by unsupervised clustering of most statistically  
83 informative genes detected as transcripts in extracted tumour tissue; the latter representing  
84 a heterogeneous mix of tumour, stromal and immune cells. Whilst able to categorise tumours  
85 into subsets by similarity, it is a blunt tool for informing therapy. We hypothesised that using  
86 signature gene sets representing tissue-specific pathway responses would reduce “noise” and  
87 provide greater therapeutic insight.

88 The *IFNG* transcript can be detected in cancer cohorts but gives weak sensitivity and, as a  
89 diffusible factor, IFN $\gamma$  can elicit a response in the tumour even when originating from  
90 peritumoural leukocytes. We hypothesised that a urothelial IFN $\gamma$ -response signature would  
91 provide a more informative means of detecting IFN $\gamma$ -signalling in a tumour. We therefore

92 applied a curated urothelial *in vitro* IFN $\gamma$ -response gene set (Supplementary Table 2) to the  
93 unsupervised clustering of BICa cohorts, yielding an “IFN $\gamma$ -signature” score.

94 The IFN $\gamma$ -signature was significantly correlated with *IFNG* transcript in all four BICa cohorts  
95 analysed (see figure legends for details). In NMIBC from the UROMOL2021 cohort [6], the  
96 IFN $\gamma$ -signature was weak in Class 2a tumours (Supplementary Fig. 3). In T1 tumours  
97 (combined from UROMOL2021 [6] and Northwestern Memorial Hospital (NMH) [7] cohorts;  
98 Fig. 2A) dichotomised into IFN $\gamma$ -signature high and low groups, recurrence was 50% more  
99 likely in patients whose tumours lacked the IFN $\gamma$ -signature (Fig. 2B). A Cox proportional  
100 hazards regression analysis of the pseudo-continuous unit-length scaled IFN $\gamma$ -signature  
101 scores in T1 tumours predicted a recurrence hazard ratio of 3.174  $p=0.0230$  (Supplementary  
102 Tables 3-4).

103 Analysis of TCGA-BLCA data [8] revealed that MIBC lacking the IFN $\gamma$ -signature were most likely  
104 to be graded histologically as lymphocyte-negative and of luminal papillary sub-type  
105 according to the consensus classification [9] (Supplementary Fig. 5). By contrast, MIBC classed  
106 as basal/squamous split into two clear subgroups (Fig. 2C). To examine any difference in  
107 outcomes associated with the IFN $\gamma$ -signature in basal/squamous tumours, the Lund MIBC  
108 cohort [10] was analysed in parallel (Supplementary Fig. 6). When dichotomised into IFN $\gamma$ -  
109 signature high and low groups, overall survival for basal/squamous tumours (pooled from  
110 TCGA-BLCA and Lund cohorts) was significantly lower in tumours with a weak IFN $\gamma$ -signature  
111 (Fig. 2D). A high survival hazard ratio of 4.846  $p=0.0006$  was predicted by Cox proportional  
112 hazards regression based on the pseudo-continuous IFN $\gamma$ -signature scores from both cohorts  
113 (Supplementary Tables 5-7).

114 Bladder cancer is a disease characterised by high mutational loads derived by different  
115 processes, whose historic contributions can be assessed using mutational signatures. IFN $\gamma$ -  
116 signature<sup>high</sup> basal/squamous MIBC tumours had significantly enriched genomic damage from  
117 APOBEC enzymes (Supplementary Fig. 7). Widespread APOBEC damage leads to tumour  
118 suppressor loss and creates neoantigens which were significantly more abundant in IFN $\gamma$ -  
119 signature<sup>high</sup> basal/squamous tumours [8]. In an inflammatory context, neoantigens would  
120 induce antigen-specific T cell immunity. Conversely, our data suggest that normal and  
121 malignant urothelium would suppress T cell activation through PD-L1/VISTA checkpoint  
122 inhibition, thereby inhibiting type-1 anti-tumour immune responses. It seems most probable  
123 that a balance becomes established between activated tumoricidal effector cells and  
124 regulatory/immunosuppressive elements.

125 To conclude, this study suggests a reconsideration of the role for IFN $\gamma$  in motivating immune  
126 clearance in non-BCG-responsive NMIBC. The IFN $\gamma$ -signature<sup>high</sup> basal/squamous MIBC  
127 tumours identified here appear to represent a target for immune checkpoint blockade.  
128 However, in the absence of IFN $\gamma$ , expression of PD-L1 is likely to be too low to provide an  
129 effective target. We suggest that BCG therapy would be most effective when combined with  
130 blocking of both the innate (VISTA [3]) and inducible (PD-L1) immune checkpoints. We  
131 anticipate the urothelium-derived transcriptomic IFN $\gamma$ -signature will prove a valuable tool for  
132 the design of more efficacious immunotherapy protocols.

133

#### 134 **CRediT Author Statement**




135 Conceptualization – SCB, JS

136 Methodology – SCB


- 137 Software – ASM, SCB, PE, GS
- 138 Formal analysis – SCB, ASM
- 139 Investigation – SCB, RGS
- 140 Data Curation – ASM, SCB, PE, GS
- 141 Writing – SCB, LKT, JS
- 142 Writing - Review & Editing – SCB, ASM, RGS, PE, GS, LKT, JS
- 143 Visualization - SCB
- 144 Supervision – SCB, JS
- 145 Project administration - SCB
- 146 Funding acquisition - JS
- 147
- 148 **Acknowledgements**
- 149 This study was funded by York Against Cancer.



150 **Figures**



152 *Fig. 1 – (A) mRNA-sequencing volcano plot for the IFN $\gamma$ -induced normal urothelial*  
153 *transcriptome. Data is expressed as transcripts per million (TPM) values and significance was*  
154 *assessed using a likelihood ratio test (LRT) to generate Benjamini-Hochberg corrected q-*  
155 *values. The volcano highlights the potential for urothelial-immune signalling via (B) observed*  
156 *shift in chemokine-related gene expression. Stars following gene names indicate >2-fold*  
157 *changes with significance \*=q<0.05, \*\*=q<0.01 and \*\*\*=q<0.001. (C) Urothelial expression*  
158 *of the family of B7 peripheral membrane protein genes. The MHC co-stimulatory molecules*  
159 *CD80 and CD86 were not expressed. CD274 (“PD-L1”) was significantly induced by IFN $\gamma$*   
160 *treatment (mean fold change = 5.2; q=0.0095). VSIR (“VISTA”) was abundantly expressed*  
161 *and significantly induced by IFN $\gamma$  treatment (mean fold change = 1.2; q=0.0322). For the x-*  
162 *axis labels, the B7-family name and other common names are provided in normal font above*  
163 *the italicised HGNC gene name. Data in all panels is derived from normal human urothelium*  
164 *established from six independent donors.*



166 Figure 2 – (A) Heatmap and  $k$  means clustering based on expression of the IFN $\gamma$ -signature  
 167 genes in the T1 tumours of UROMOL2021 and Northwestern Memorial Hospital (NMH)  
 168 cohorts ( $n=236$ ). The IFN $\gamma$ -signature shows a Spearman rank correlation of 0.66 ( $p=4 \times 10^{-31}$ )  
 169 with the IFNG gene in T1 tumours. The full UROMOL2021 cohort is shown as Supplemental  
 170 Fig. 3; [6]). The separate NMH T1 cohort ( $n=99$ ; [7]) is shown as Supplemental Fig. 4. (B)  
 171 Kaplan-Meier analysis of IFN $\gamma$ -signature high and low T1 tumours with survival data from  
 172 UROMOL2021 and NMH cohorts combined ( $n=201$ ). The Kaplan-Meier curve is truncated but  
 173 no events were recorded after the truncation. A Cox proportional hazards regression was  
 174 also performed using the unit-length scaled IFN $\gamma$ -signature values from T1 tumours which

175 *predicted a recurrence hazard ratio of 3.174  $p=0.0230$  (Supplementary Table 4). (C)*

176 *Heatmap for expression of the  $IFN\gamma$ -signature in the Basal/Squamous group of TCGA MIBC*

177 *tumours ( $n=151$ ; full cohort is shown as Supplemental Fig. 5; [8]; shown classified in red*

178 *according to the consensus report [9]). The  $IFN\gamma$ -signature shows a Spearman rank*

179 *correlation of 0.87 ( $p=3.85 \times 10^{-47}$ ) with the *IFNG* gene in Ba/Sq TCGA-BLCA tumours. Similar*

180 *analysis for the Lund MIBC cohort ( $n=88$ ; [10]) is shown as Supplemental Fig. 6. (D) Kaplan-*

181 *Meier analysis of the  $IFN\gamma$ -signature in Basal/Squamous tumours from TCGA and Lund MIBC*

182 *cohorts combined ( $n=232$ ). The Kaplan-Meier curve is truncated but no events were recorded*

183 *after the truncation. A Cox proportional hazards regression was also performed using the*

184 *unit-length scaled  $IFN\gamma$ -signature values from both cohorts which predicted a hazard ratio of*

185 *4.846  $p=0.0006$  (Supplementary Table 7).*

186 **References**

- 187 [1] Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G. Bacterial immunotherapy for  
188 cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma  
189 signaling. *Proc Natl Acad Sci U S A*. 2020;117:18627-37.
- 190 [2] Riemensberger J, Bohle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local  
191 tumour surveillance in a syngeneic model of orthotopic bladder cancer. *Clin Exp Immunol*.  
192 2002;127:20-6.
- 193 [3] Yum JI, Hong YK. Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista,  
194 baby. *Front Oncol*. 2021;11:658488.
- 195 [4] Vollmer T, Schlickeiser S, Amini L, et al. The intratumoral CXCR3 chemokine system is predictive  
196 of chemotherapy response in human bladder cancer. *Sci Transl Med*. 2021;13.
- 197 [5] Baker SC, Mason AS, Slip RS, et al. BK polyoma virus (BKPv) is a risk factor for bladder cancer  
198 through its induction of APOBEC3-mediated genomic damage. *bioRxiv*.  
199 2021;<https://doi.org/10.1101/2021.05.13.443803>.
- 200 [6] Lindskrog SV, Prip F, Lamy P, et al. An integrated multi-omics analysis identifies prognostic  
201 molecular subtypes of non-muscle-invasive bladder cancer. *Nat Commun*. 2021;12:2301.
- 202 [7] Robertson AG, Groeneveld CS, Jordan B, et al. Identification of Differential Tumor Subtypes of T1  
203 Bladder Cancer. *Eur Urol*. 2020;78:533-7.
- 204 [8] Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive Molecular Characterization of Muscle-  
205 Invasive Bladder Cancer. *Cell*. 2017;171:540-56 e25.
- 206 [9] Kamoun A, Reynies A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive  
207 Bladder Cancer. *Eur Urol*. 2019.
- 208 [10] Sjobahl G, Eriksson P, Liedberg F, Hoglund M. Molecular classification of urothelial carcinoma:  
209 global mRNA classification versus tumour-cell phenotype classification. *J Pathol*. 2017;242:113-25.